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Abstract: Even though the treatment of human immunodeficiency virus (HIV)-infected individuals 
with highly active antiretroviral therapy (HAART) provides a complete control of plasma viremia to 
below detectable levels (40 copies/mL plasma), there is an unequal distribution of all antiretroviral 
drugs across diverse cellular and anatomic compartments in vivo. The main consequence of this 
is the acquisition of resistance by HIV to all known classes of currently prescribed antiretroviral 
drugs and the establishment of HIV reservoirs in vivo. HIV has a distinct advantage of surviving 
in the host via both pre-and postintegration latency. The postintegration latency is caused by inert 
and metabolically inactive provirus, which cannot be accessed either by the immune system or 
the therapeutics. This integrated provirus provides HIV with a safe haven in the host where it is 
incessantly challenged by its immune selection pressure and also by HAART. Thus, the provirus 
is one of the strategies for viral concealment in the host and the provirus can be rekindled, through 
unknown stimuli, to create progeny for productive infection of the host. Thus, the reservoir 
establishment remains the biggest impediment to HIV eradication from the host. This review 
provides an overview of HIV reservoir sites and discusses both the virtues and problems associated 
with therapies/strategies targeting these reservoir sites in vivo.
Keywords: HIV , HAART, reservoirs, compartmentalization, elimination strategies for reser-
voirs, AIDS
Introduction
Since the discovery of human immunodeficiency virus (HIV) type 1 and the recognition 
that HIV is the causal agent of acquired immunodeficiency syndrome (AIDS) in 1983,1 
over 25 million people have died of AIDS. It is estimated that 33 million people are 
now currently living with the deadly disease.2 Among the 33 million infected 92.7% 
are adults, 46.4% are females, and 7.5% are children. In the year 2007, the World 
Health Organization estimated that 2.7 million people were newly infected with HIV 
and a further 2 million people died of AIDS-related diseases that year. Of the 33 mil-
lion currently living with AIDS, 68% of the individuals are living in the sub-Saharan 
Africa. Following that, South East Asia is the next largest region affected by HIV and 
accounts for an estimated 12% of the globally infected population. Individuals with 
AIDS, who live in North America, Latin America and Eastern Europe to central Asia, 
account for an estimated 4% each. It is therefore not surprising that the majority of 
people living with HIV inhabit the world’s poorest regions. This is due to the lack of 
access to HIV prevention and treatment among the poor and marginalized populations.3 
This has resulted in the continual dissemination of the virus among marginalized 
populations.
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The introduction of highly active antiretroviral therapy 
(HAART) has provided HIV patients with a prolonged life 
and has led to a considerable decline in co-morbidities and 
mortality in HIV patients. Even though a significant proportion 
of HIV-infected individuals receiving antiretroviral treatment 
can achieve below detectable limits (BDL) of plasma viremia 
(40 copies/mL),4 the acquisition of drug resistance by HIV 
to practically all currently prescribed classes of antiretroviral 
drugs is the biggest impediment to the clinical management 
of HIV patients and the successful outcome of antiretroviral 
therapy.
HIV can continue to replicate at very low levels even 
during effective HAART. Persistent infection of nonactivated 
T-lymphocytes (where low levels of viral replication occurs) 
has been detected in individuals on successful HAART with 
BDL.5 Thus, it is apparent that HAART exerts considerable 
selection pressure on HIV , which provides partial restoration 
of the host immune system. In this tussle HIV is a winner, as it 
is able to conceal itself by establishing reservoir and sanctuary 
sites, which show disparate and suboptimal drug penetration. 
As a consequence the suboptimal drug concentrations, that 
reside in these diverse reservoir sites, encourage the emer-
gence of drug-resistant HIV strains. In addition, HIV is also 
able to safeguard its survival in the face of HAART and strong 
host immune selection pressure through proviral integration 
into the host genome. This provirus being inert to the host 
immune system is ideal for latent reservoir establishment in 
vivo. Latent cellular reservoirs may hinder attempts at HIV 
eradication. Latency is a common feature of all retroviruses 
and is one of the most important host cell-virus interactions 
whereby the virus can survive and persist in the face of the 
immune response and antiviral therapy. Of major concern is 
the re-emergence and spread of HIV-1 variants from reser-
voirs after the withdrawal or failure of HAART because the 
emerging variants are as fit as, or in some cases fitter than 
the wild type virus.
Although much has been learnt about the mechanisms and 
sites of HIV persistence and reservoir establishment during 
drug therapy,6,7 the failure to eliminate latent viral reservoirs 
is a major shortcoming of the current HAART regimens.8 
New strategies are being developed to flush virus out of these 
reservoirs, which may provide the complete eradication of 
HIV in vivo in the future.
The present review is focused on HIV reservoirs and 
the eradication of HIV from them. It attempts to provide 
a comprehensive overview of what we have achieved so 
far in the understanding of HIV reservoirs, strategies to 
overcome the establishment of and viral elimination from 
these reservoirs; in addition to approaches and products in 
the pipeline for eliminating HIV from these reservoir sites.
Definition of a viral reservoir
A viral reservoir is a cell type or anatomical site, where a 
replication-competent form of HIV can accumulate and persist 
stably. The definition of a viral reservoir should have two vital 
elements for it to be termed “reservoir”. To be biologically 
significant, a reservoir must preserve some replication 
viable virus, which can provide for the replenishment of 
the population of infected cells in the future. The second 
element for qualifying as a viral reservoir is stability; where 
viruses can persist either as virions or in infected cells in 
order to safeguard the future continuation of viral progeny 
in the host.
Tissue and cellular reservoirs  
of HIV
Two major reservoirs for HIV have been recognized: 
anatomical and cellular. A viral reservoir may be defined 
as an anatomical site or cell type in which a replication-
competent form of HIV persists, accumulating with more 
stable kinetic properties than the circulating pool of actively 
replicating virus.6,9 A reservoir can be classified as latent, 
if the infected cells are not producing virus but retain the 
capacity to do so. HIV has been shown to target many 
different cell types, and a number of major tissue reservoirs 
of the virus are evident within infected individuals. The 
ability of the virus to colonize diverse cellular and tissue 
targets contributes strongly to persistence in the setting of 
HAART, and is responsible in part for the emergence of 
antiretroviral drug resistance.
Tissue reservoirs
A number of anatomical sites may act as reservoirs of 
HIV replication including the lymphoid tissue, gastro-
intestinal tract, brain/central nervous system (CNS), 
genital tract, semen, and the lung.10–15 These structures are 
immunologically sheltered or separated by a barrier from 
the blood and lymphoid systems. Some anatomical sites 
may be non-permissive to immune surveillance and effective 
drug penetration, thus serving as potential sites of persistent 
HIV replication eg, the respiratory, gastrointestinal, and 
reproductive tracts. These reservoirs are either established 
early in the course of HIV infection or during HAART.8,16 
Differential viral evolution in these sites as compared to the 
blood compartment has been observed, and may be indica-
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replication.15 The optimal delivery of antiretroviral therapies 
to these different anatomical sites is also important in the con-
text of both viral eradication and preventing the emergence 
of drug-resistant HIV variants.
Peripheral lymphoid tissue
HIV generally enters the human host via mucosal surfaces 
and is subsequently disseminated throughout the lymphatic 
tissues, which then become a major reservoir of virus 
throughout the course of infection.17–19 Initial colonization 
of lymphoid tissue is thought to be mediated by dendritic 
cells (DCs) and macrophages, which associate with the virus 
at the mucosal surfaces and transport it to the lymph nodes 
where the initial infection of CD4+ T lymphocytes occurs. 
Although lymphoid tissues are considered the primary site 
of CD4+ T cell infection over the course of the disease, 
follicular dendritic cells (FDCs) are the major source of 
viral RNA in lymphoid tissue. Measurement of viral pools in 
lymphoid tissue during the asymptomatic phase of infection 
has revealed an extremely large FDC pool of approximately 
1011 copies of viral RNA, exceeding the viral RNA in 
productively infected cells by more than 50 fold.20 The level 
of HIV-1 RNA in virions associated with FDCs is also two 
orders of magnitude greater than plasma levels during this 
phase of infection.20 This indicates that the measurement of 
plasma HIV levels greatly underestimates the viral burden 
and that lymphoid tissue is a major reservoir site where HIV 
is stored. In the later stage of infection, there are comparable 
quantities of virus stored in the FDC pool,21 although earlier 
in infection the FDC pool is somewhat smaller and closer 
in size to the viral load in productively infected cells. In 
addition to viral burden, lymphoid tissue is the major site of 
HIV production in the body.20,21
The pattern of productive infection in lymphoid tissue 
is consistent with cell-to-cell transmission from one cell to 
another activated T cell in its vicinity.22 The localized nature of 
virus production in lymphoid tissue is implied by observations 
of foci of infected cells,17 and evidence of founder effects in 
viral populations derived from single white pulps.22,23 The 
inhibitory effect of HAART on both viral replication and 
the levels of virus in the blood and in lymphoid tissues is 
well documented, and has been consistent over a number of 
studies.21,24–26 Little or no viral RNA is detectable in the FDC 
pool, in total RNA extracted from lymphoid tissue, or in cells 
isolated from lymphoid tissue, when plasma viremia is sup-
pressed to below detectable levels. However, chronically and 
latently infected CD4+ T cells persist24 and represent potential 
focal points of viral reproduction upon cessation of therapy.5 
In addition, chronically infected cells and replication of less 
fit drug-resistant viruses result in the continued evolution of 
genotypic drug resistance.27
The gastrointestinal tract
The gastrointestinal tract mucosa is the largest lymphoid organ 
in the body.28 Due to a large population of activated CXCR4+ 
CCR5+ target cells, the gastrointestinal mucosa represents a 
favored target for HIV-1 infection29 and appears to support 
enhanced HIV-1 replication in comparison to other body 
compartments.30–32 With the exception of parenteral transmis-
sion, almost all vertical and homosexual transmission of HIV 
occurs via the gastrointestinal tract. Virus inoculated into the 
gastrointestinal tract of the fetus or infant is likely to enter 
the gut associated lymphoid tissue through tonsillar and/or 
upper intestinal mucosa. Homosexual transmission of the 
virus occurs through orogenital or anogenital contact. The 
efficiency of HIV transmission across the gastrointestinal 
mucosa depends upon factors including: donor blood viral 
levels;33,34 the pre-existence of genital tract infection and local 
inflammation;35 mucosal integrity; genetic predisposition; and 
behavioral factors. Potential cellular routes in the transloca-
tion of HIV across the epithelium include: mucosal cells,36,37 
DCs;38 and epithelial cells.39 Epithelial cells appear to be 
the most predominant viral transfer mechanism, selectively 
transporting R5 tropic viruses, which are the predominant 
phenotype of the majority of transmitted viruses.39
The gastrointestinal mucosa contains a large proportion 
(40%–60%) of the body’s lymphocyte population40 and is the 
largest reservoir for macrophages in the body.41 Furthermore, 
the majority of mucosal CD4+ T lymphocytes are of the 
activated memory phenotype42 providing a ready target for 
HIV-1 infection.43 This heightened state of cellular activation 
arises from elevated levels of pro-inflammatory cytokines 
released in response to foreign antigens and bacterium. 
Several studies have demonstrated that in addition to similar 
levels of CXCR4 expression, mucosal mononuclear cells have 
a higher predominance of CCR5 expression than peripheral 
blood cells, thus increasing susceptibility to infection by 
primary HIV-1 isolates.44 Although large numbers of intestinal 
macrophages exist in the subepithelial lamina propria, these 
differ markedly in phenotype and function from blood 
monocytes,45,46 and are poorly permissive to HIV infection.47 
Although the prevalence of HIV-infected macrophages in the 
mucosa is low (0.06% of lamina propria mononuclear cells),48 
the extremely large size of the gastrointestinal mucosa makes 
intestinal macrophages a prominent reservoir of HIV. In 
contrast, epithelial lymphocytes express CXCR4 and CCR5 HIV/AIDS - Research and Palliative Care 2010:2 106
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and support replication by X4 and R5 viruses,39,49 and it is 
likely that these are the initial target cell for HIV after upper 
gastrointestinal tract inoculation. From the mucosa, virus is 
disseminated to systemic sites initiating large-scale depletion 
of CD4+ T cells first in the intestinal lamina propria and 
subsequently in the blood.
The central nervous system
The CNS is a key anatomical reservoir of HIV-1 in both 
therapy-experienced and therapy-naïve patients.16 The CNS 
is protected by two formidable barriers: the blood–brain 
barrier which tightly segregates the brain from the cir-
culating blood, and the blood–cerebrospinal fluid barrier 
in the epithelium of the choroid plexus, which limits the 
passage of molecules and cells into the cerebrospinal fluid. 
This barrier-mediated separation of the CNS gives rise to 
an altered immunological environment, and also provides 
an obstacle to therapeutic measures such as antiretroviral 
therapy. For these reasons, the CNS represents a unique site 
for viral replication in HIV-infected patients, particularly in 
the setting of HAART.16
HIV enters the CNS early in the course of systemic 
infection,50 and is present at all subsequent stages. As a result 
of CNS infection, patients may suffer from a range of clinical 
symptoms, the most notable being dementia.51 Prototype 
HIV-1 isolates from the CNS are typically R5 nonsyncytium 
inducing M tropic strains. Macrophages and microglia are 
the principle target cells for productive infection in the 
CNS.52,53 Both infection and activation of these cell types 
appears to be critical for the development of dementia.54 
Recently, HIV DNA has been detected in cortical and basal 
ganglia-derived astrocytes, and it is believed that astrocytes 
may serve as a viral reservoir in the brain.55 Gene microar-
ray analysis has shown that HIV-1 alters the programme of 
gene expression in astrocytes, including changes in tran-
scripts encoding cytokines. HIV infection also inhibits the 
capacity of astrocytes to clear glutamate, a feature likely 
to affect neuronal activity or survival and contribute to 
HIV neuropathogenesis.56 Although there is no firm in vivo 
evidence that neurons can support HIV-1 infection, recent 
in vitro experiments have demonstrated the ability of neu-
rons to sustain transient productive infection for brief time 
periods.57
The mechanisms of HIV-1 penetration into the CNS 
are uncertain. Some evidence exists that HIV-infected bone 
marrow-derived monocytes may transport HIV across the 
blood–brain barrier.58,59 Blood-derived microglia have also been 
suggested to transport HIV across the blood–brain barrier.60 
A second putative mechanism of HIV entry into the CNS is a 
mechanism involving the passage of HIV from the blood to the 
cerebrospinal fluid, then into the choroid plexus and ventricles 
and thus into the brain. Supporting this, productive viral infec-
tion occurs in the choroid plexus, predominantly in stromal 
macrophages and DC.61–64 The incidence of HIV-1 infection in 
the choroid plexus exceeds that of the brain, and also occurs 
prior to the onset of AIDS and immunosuppression.63 It is 
thought that the greater vascular permeability of the choroid 
plexus may render it more susceptible to HIV-1 infection, 
and may facilitate heterogeneous dissemination of the virus 
to the brain. Supporting this, studies have shown that choroid 
plexus HIV sequences are admixtures of brain-and blood-
derived isolates65 and are common in asymptomatic HIV-
infected patients.66 Due to the presence of the blood–brain 
and blood–cerebrospinal fluid barriers, suppression of HIV 
populations in the CNS with antiretroviral drugs is problematic. 
Drug penetration into the CNS is poor, and the maintenance 
of effective drug concentrations is difficult. These are some 
of the problems influencing the treatment of HIV infection 
in the CNS.
Reproductive tract
Both the male and female genital tracts are potential 
reservoirs for HIV . Each has a distinct microenvironment 
that permits viral replication independent from the systemic 
circulation.67,68 The male genital tract possesses unique 
vascular features, including the blood–testis barrier, formed 
by specialized tight junctional complexes between Sertoli 
cells that prevent free ingress of substances from the testicular 
interstitium to the seminiferous epithelium.69 In addition to 
cell-free HIV particles, T lymphocytes and macrophages 
isolated from semen of HIV-infected men harbor provirus.70,71 
A differential source of virus in semen and blood has been 
suggested by a number of studies, providing evidence that the 
male reproductive tract is a distinct reservoir of virus in HIV-
infected men. An absence of correlation between plasma and 
semen viral loads has been reported by several investigators 
suggesting independent viral replication.72,73 HIV infection 
of the testis has been described,74 and CD4 is detectable on 
the cell surface of lymphocytes and macrophages infiltrating 
the testis, suggesting these cells are potentially infectable by 
HIV .75 HIV-infected cells of the lymphocytic/monocytic type 
have been found in seminiferous tubules and interstitium 
of the testis, and these cells were also observed in semen.75 
Other possible targets of HIV infection in the testis include 
spermatogonia, spermatocytes and spermatids,76,77 and 
residual germ cells.78HIV/AIDS - Research and Palliative Care 2010:2 107
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Multiple cells and tissues in both the upper and lower 
female reproductive tract are susceptible to HIV infection,79 
and histopathological studies have clearly demonstrated 
the genital tract of HIV-infected women is an active site for 
viral replication, especially in the submucosa of the cervical 
transformation zone.80 HIV infection has been demonstrated 
in a range of tissues within the female genital tract, including: 
epithelial and stromal cells of the uterus and fallopian 
tube; cervix; and ectocervix.79 Virus in the genital tract of 
HIV-infected women also has its own dynamics that are 
partly independent of the systemic compartment, supporting 
the female genital tract as an HIV reservoir.80 Genital tract 
shedding has been found to occur in women on HAART with 
less than 500 viral copies per milliliter of plasma, suggesting 
a separate reservoir of HIV-1 replication.81
The lung and kidneys
Both the lung and kidneys have been suggested to act as 
reservoirs of virus in HIV-infected individuals, however, 
the significance of these organs during the course of disease 
remains uncertain. HIV can be detected frequently and 
recovered from both alveolar macrophages and alveolar 
lymphocytes.82,83 HIV is most commonly recovered from 
the alveolar lymphocytes indicating that the virus is carried 
into the lungs by these cells as they migrate from the blood 
in response to opportunistic infections. Although distinct 
populations of the virus have been detected between the 
blood and lung, more homogeneous populations have been 
detected in the lung with low copy number suggesting a lack 
of replication. The low level of RNA detected in alveolar mac-
rophages also suggests the lung is of limited importance as a 
site of HIV replication.83,84 However, larger amounts of HIV 
RNA have been detected in bronchoalveolar lavage fluid.85,86 
Some discordance between drug resistance mutations in 
the RT gene of HIV from bronchoalveolar lavage fluid and 
plasma has also been reported.86
The kidney represents another site of localized HIV 
replication, and has been an organ of particular interest due 
to the occurrence of HIV-associated nephropathy. Renal glo-
merular and tubular epithelial cells have been shown to harbor 
both HIV DNA and mRNA, suggesting productive infec-
tion.87,88 Circularized viral DNA has also been found in kidney 
biopsies suggesting active replication in renal tissue, although 
infiltrating infected leukocytes harbor more viral mRNA 
than renal epithelium.87 Productive HIV infection in renal 
epithelial cells was recently confirmed by in situ hybridization 
polymerase chain reaction (PCR), and phylogenetic analyses 
of kidney-derived sequences conducted in the same study 
revealed evidence of tissue-specific evolution when compared 
to those of peripheral blood mononuclear cells.88 The com-
bination of productive and independent HIV infection in a 
localized manner within the renal tissue suggests the exis-
tence of a renal viral reservoir.
Cellular targets and reservoirs
A wide-range of cell types distributed amongst a number 
of different tissues are susceptible to HIV infection. CD4+ 
T lymphocytes89 and macrophages90 are the primary cellular 
targets of HIV . Other infectable cell types include: monocytes, 
CD8+ T lymphocytes; natural killer (NK) cells; peripheral 
blood and FDCs; B cells; and an array of specialized cell 
types derived from various tissue reservoirs of HIV (eg, renal, 
mucosal, and cervical epithelial cells; astrocytes and microglia 
in the CNS; skin fibroblasts; and bone marrow stem cells). 
However, the infection of a number of putative cellular HIV 
targets remains controversial, and a contribution to HIV 
pathogenesis is often unclear.
CD4+ T lymphocytes
The hallmark of HIV-1 infection is the progressive depletion 
of CD4+ T lymphocytes. CD4+ T cell tropic HIV strains are 
designated X4 viruses as they predominantly use the CXCR4 
co-receptors for cellular entry. X4 viruses are associated with 
increased replication, and syncytium inducing infection.91 
Reflecting this, HIV infection of CD4+ T cells is cytopathic 
and leads to extensive cell death.92 CXCR4 is widely 
expressed and present on both naive and memory CD4+ T 
cells.93 HIV entry and subsequent replication in CD4+ T cells 
requires cellular activation,94 which leads to an increase in the 
size of the nucleotide pool required for viral DNA synthesis 
and the level of transcription factors.94 The majority of CD4+ 
T lymphocytes in the blood are in a resting non-activated 
state and thus are not susceptible to infection.95 Despite this, 
CD4+ T lymphocytes are still the principle cellular reservoir 
of HIV .
HIV-1 infection of CD4+ T lymphocytes is thought 
to occur predominantly in lymphoid tissue, where there 
is close contact with other infected leukocytes including 
antigen presenting cells.19,96 The pattern of productive 
infection in lymphoid tissue is consistent with cell-to-cell 
transmission, from one cell to another activated T cell in 
its vicinity.22 Within lymph nodes, germinal centre CD4+ T 
cells represent an important site of HIV replication in vivo.97 
Lymphoid tissue biopsies from HIV-infected patients have 
also suggested that CD4+ T cells remain the major source 
of HIV-1 production in the end-stage of the disease.98 The HIV/AIDS - Research and Palliative Care 2010:2 108
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gastrointestinal tract is a major site of CD4+ T cell depletion 
and HIV replication.99 A large proportion of the body’s lym-
phocyte population resides in the gastrointestinal mucosa,40 
and the intestine contains an abundance of activated memory 
CD4+ T cells, which are favored targets of HIV infection. 
CD4+ T cells are also likely to become infected in the thy-
mus,100 and the depletion of CD4+ thymocytes through the 
destruction of CD4+/CD8+ precursor cells may play a signifi-
cant role in the pathogenesis of HIV-1 disease. Analyses have 
demonstrated the emergence of cytopathic and tissue-specific 
HIV variants in the thymus.100 Furthermore, CXCR4 expres-
sion is modulated during T-lymphoid differentiation such 
that immature thymocytes display an increased frequency 
and higher surface density of the coreceptor than do more 
mature cells.101 High levels of both primary receptor and 
coreceptor may therefore be responsible for the efficient 
infection of the thymus, and could in part account for the 
rapid disease progression observed in HIV-infected children, 
where the thymus is actively involved in the production of 
new T lymphocytes.101
Much debate exists over the mechanisms of CD4+ T cell 
depletion by HIV . At the outset, it is important to realize that 
the fall in CD4+ numbers is not only a result of CD4+ T cell 
destruction, but also stems from impaired production. Early 
suggestions of cytopathic destruction of CD4+ T cells102,103 
were complicated by observations that there were many 
more cells dying than there were infected cells. It was soon 
realized that a number of other mechanisms were responsible 
for CD4+ T cell death and the subsequent decline in numbers. 
Both the destruction of mature CD4+ T cells and the impaired 
production of new cells can be attributed to both direct and 
indirect effects of the virus.
One of the central immunological defects in HIV-infected 
individuals is a weak or absent CD4+ T helper proliferative 
response.104 When present these responses correlate directly 
with decreased plasma viremia. The clinical stages of HIV 
disease are also firmly linked with the CD4+ T cell dynamics 
over time during the infection. CD4+ T cell numbers decline 
sharply during the acute phase of infection, partially 
rise again and then slowly decline once more during the 
asymptomatic phase until counts fall below 200 cells per 
microliter of blood, which marks the progression to AIDS. 
The emergence of CD4-tropic (X4) viruses is associated with 
rapid CD4+ T cell decline and disease progression.105 In the 
years after chronic infection is established, X4 strains emerge 
in approximately 50% of infected individuals. The associa-
tion between X4 virus and acceleration of HIV-1 disease 
progression has been attributed to the expanded spectrum 
of CXCR4+ precursor cells susceptible to infection by X4 
strains. It has also been postulated that the decline of the host 
immune system associated with clinical AIDS may allow X4 
viruses to evolve and replicate more freely in later stages of 
infection.105 The establishment of latent HIV infection in 
resting memory CD4+ T cell subsets early in infection is of 
primary importance in the persistence and continued evolu-
tion of HIV , particularly in the setting of potent antiretroviral 
therapy.
Emerging concepts on central memory  
and transitional memory CD4+ T cells
New data shows that the central memory (TCM) and 
transitional memory (TTM) CD4+ T cells define major cel-
lular reservoirs for HIV , where viral persistence occurs by 
two different mechanisms. Primarily, HIV persists in the 
TCM cells in subjects showing reconstitution of the CD4+ 
compartment upon HAART. The maintenance of this reservoir 
is through T cell survival and low-level antigen-driven 
proliferation, which is slowly depleted over time. In contrast, 
preferential detection of proviral DNA is a feature of TTM 
cells from aviremic individuals with low CD4+ counts and 
higher amounts of interleukin-7-mediated homeostatic 
proliferation. This mechanism ensures persistence of these 
cells in vivo. Chomont and colleagues106 have identified two 
viral reservoirs within the memory CD4+ T cell subsets of 
virally suppressed subjects. The TCM reservoir is the major 
long-lasting reservoir in immune responders to HAART. As 
TCM cells are characterized by their extremely low degree of 
cellular proliferation, and, because of their intrinsic capacity 
to survive for decades, these cells provide a long-lasting 
cellular reservoir for HIV-1.
The second paper, by Brennan and colleagues,107 uses 
genetic analyses of HIV sequences to show that there is a 
reservoir of virus that seems to be coming from a cell type 
other than memory CD4+ T cells. This study shows that 
in most cases, the residual virus detectable in individuals 
on suppressive ART is genetically distinct from the virus 
found in the memory CD4 T cells. Therefore, if much of the 
residual viremia in HIV patients on HAART arrives from 
other reservoir sites, as suggested, the eradication strategies 
need to be revisited for purging reservoir virus.
CD8+ T lymphocytes
Although debate still exists over the significance of HIV 
infection of CD8+ T lymphocytes, there is little doubt that 
HIV can productively infect these cells. Reports of CD8+ 
T cell infection have occurred on a regular basis since the HIV/AIDS - Research and Palliative Care 2010:2 109
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early stages of the epidemic. Initially, CD8+ T cell infection 
was described in vitro.108 These reports were followed by evi-
dence that CD8+ T cells harbor and express HIV-1 in vivo,109 
and may express small amounts of CD4+ RNA.109
Much of the research conducted on the HIV infection of 
CD8+ T cells has focused on the mechanism of viral entry, 
and the origins of CD8+ cell infection. Evidence suggests 
that CD8+ T cells become infected through a conventional 
CD4-dependent mechanism during their maturation in the 
thymus, at the double-positive (DP) stage where CD4 is 
co-expressed with CD8. Implants of human thymic tissue 
containing infected DP thymocytes in severe combined 
immunodeficiency (SCID) mice have been shown to 
produce infected single positive (SP) CD8+ T lymphocytes 
in the peripheral circulation.110 HIV-1 proviral DNA is also 
preferentially distributed in the naïve (CD45RA+) subset of 
CD8+ T cells, further supporting the thymus as a source of 
CD8+ T cell infection.111
In addition to possible intrathymic mechanisms, 
stimulation of highly purified CD8+ T cells with mitogens, 
allogeneic DC or anti-CD3 and anti-CD28 antibodies 
in vitro leads to de novo synthesis of CD4 and susceptibility 
to HIV-1 infection.112 Activated subsets of circulating 
CD8+ T lymphocytes express high frequencies of CD4 in vivo, 
rendering these cells vulnerable to viral destruction.113,115 
Reports of CD8+-mediated CD4 independent entry into CD8+ 
T cells have also been provided by Saha and colleagues.115 
Multiple CD8+ clones generated from patients with AIDS 
were characterized and it was found that several were 
CD8 single positive and endogenously infected by HIV .115 
Subsequent biological characterization of these isolates 
demonstrated CD8-mediated cell entry without the require-
ment for any known chemokine coreceptor.115 Recent work 
by this group has lead to further characterization of CD4-
independent entry.115
In addition to clarification of CD8+ T cell entry 
mechanisms, several studies have focused on quantitative 
aspects of CD8+ infection by HIV . Several reports have sought 
to compare the abundance of HIV provirus in CD8+ cells 
with those of other leukocytes. It has been concluded that 
CD8+ T cells harbor substantial amounts of provirus. Liv-
ingstone and colleagues found that in the late stages of the 
disease, infection in CD8+ T cells accounts for between 
66% and 97% of total proviral DNA; there is an inverse 
relationship between CD8+ T cell counts and the frequency 
of CD8+ T cell infection.116 Similarly, more recent reports 
have found that CD8+ T cells contain significant amounts 
of provirus.111,113 Additional studies have also attempted to 
clarify the distribution of proviral DNA in specific CD8+ T 
cell subsets. One report demonstrated preferential distribu-
tion of HIV in the naive (CD45RA+) subset of CD8+ T cells 
compared to the memory/effector (CD45RO+) population. 
In contrast to all previous findings, one recent report has 
suggested that naïve and memory CD8+ T cells are rarely 
infected by HIV.113
Currently there is debate over whether the infection of 
CD8+ T cells contributes significantly to the immunodeficiency 
observed in AIDS. This stems from the existence of a number 
of other possible mechanisms that could account for the 
numerical decline and functional impairment of CD8+ cells 
observed in the progression of the disease. These include 
increased susceptibility to apoptosis from alterations in the 
cytokine milieu in lymphoid tissue; bystander effects from 
neighboring productively infected CD4+ T cells, or toxicity 
from the release of HIV derived proteins such as gp120 or 
Tat.117 Loss of CD4+ helper function leading to impaired 
clonal expansion and function of CD8+ T lymphocytes 
on antigenic pressure also contributes.118 Thymic destruction 
of CD8 precursor cells has been proposed as an explanation 
for the eventual failure of CD8 homeostasis; the decline 
in circulating numbers of first naïve and then memory 
CD8+ T cells upon disease progression;119 and the recovery 
in naïve CD8+ numbers on commencement of antiretroviral 
therapy.120
Macrophages
Macrophages represent a key target of HIV in addition to 
CD4+ T lymphocytes. Although CD4 surface expression on 
macrophages is lower than on CD4+ T cells, and the number 
of infected macrophages in the body is relatively low in 
comparison,121 macrophages still produce large amounts of 
virus.122 HIV in macrophages is produced on the complex 
surfaces between cells, on free surfaces, and in cytoplasmic 
vacuoles of the Golgi apparatus.123 In addition to producing 
new virions, macrophages spread viral particles to bystander 
CD4+ T lymphocytes through a fusion mechanism,124 and 
activation of the oxidative pathway in infected macrophages 
may also lead to apoptotic death of noninfected bystander 
cells.117
Macrophages are a primary agent of viral dissemina-
tion with a widespread distribution, and are the principal 
infected cell type in many tissues (eg, CNS).125 Macrophage 
HIV isolates (M-tropic) are predominantly R5 strains, 
associated with slower and nonsyncytiumni-inducing 
infection.126 The infection of macrophages is predomi-
nantly mediated through CCR5, and M-tropic variants are HIV/AIDS - Research and Palliative Care 2010:2 110
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preferentially transmitted.127 Although macrophages have 
been shown to express CXCR4,128 they are believed to 
impose a restriction on the replication of X4 virus at the 
intracellular level.129
Macrophages provide a different environment for HIV 
that is distinct from the milieu in lymphocytes. In contrast 
to lymphocytes, macrophages are in a stage of terminal 
differentiation and have a limited potential for proliferation.130 
They are insensitive to the cytopathic effect of the virus, 
and the long life span of infected macrophages probably 
compensates for their relatively low number, substantiating 
their contribution to viral production.131 Short-term dynamics 
in productively infected CD4+ T cells are characterized by a 
rapid exponential increase of virus replication followed by 
extensive cell death. In contrast, macrophages can produce 
and release high levels of the virus over an extended time 
period,132 categorizing them as chronically and persistently 
infected cells.6 Signal transduction pathways in macrophages 
differ substantially from those of T cells. Such pathways can 
be modulated by HIV and contribute to the regulation of cell 
susceptibility to infection.133 For example, different CD45 
isoforms are expressed by naïve and memory CD4+ T cell 
subsets. The signal transduction molecule p56lck is present 
on CD4+ T cells but absent on macrophages, correlating with 
CD4 endocytosis in macrophages.134 There are differences in 
the infectivity of viruses produced by macrophages,125 and 
limited nucleotide precursors in macrophages can result in an 
increased time period for viral replication.135 However, some 
studies have shown similar kinetics in both macrophages and 
lymphocytes,136 while others have demonstrated that primary 
isolates replicate at higher levels in macrophages compared 
to T cells.137
Although macrophages are most likely to be a significant 
source of HIV during the second, slower phase of decay,138 it 
has been suggested that latent infection may be established 
in macrophages. Latently infected macrophages have been 
observed in large numbers throughout the lymphoid system 
from the early to late stages of infection.139 In addition, the 
unusual dynamics of replication in macrophages and the 
unique characteristics of these cells result in altered responses 
to antiretroviral therapy.
Monocytes
HIV infection of circulating blood monocytes was reported 
early in the epidemic.140 These initial reports made it 
unclear as to whether monocyte infection is latent or 
productive. Subsequent studies found levels of proviral 
DNA in monocytes to be relatively low or undetectable 
in comparison to T cell compartments.141 However, more 
sophisticated approaches using in situ hybridization 
coupled with simultaneous surface immunophenotyp-
ing revealed a higher incidence of monocyte infection, 
and demonstrated the production of viral mRNA in 
monocytes indicating productive infection.142 Despite the 
apparent production of viral mRNA, other in vitro stud-
ies indicated that HIV replication was blocked prior to 
reverse transcription and integration.143 Following this, 
replication-competent virus was shown to be recoverable 
from blood-derived monocytes upon stimulation and dif-
ferentiation into macrophages.144
Recent studies have investigated the levels of cell-
associated viral DNA, mRNA and the genetic evolution 
of HIV over the course of infection.145 Monocytes isolated 
from blood have been shown to contain unintegrated circu-
lar viral DNA and multiply spliced RNA suggesting their 
infection is recent and transcriptionally active rather than 
latent.146 Zhu and colleagues observed that blood-purified 
monocytes harbored HIV DNA over time in both untreated 
and therapy-suppressed individuals.145 Viral decay in mono-
cytes was considerably slower on average than that in activated 
and resting CD4+ T cells. In addition, the average half-life 
of HIV DNA in monocytes was considerably longer than 
the estimated mean intermitotic lifespan of monocytes and 
macrophages,138 suggesting renewal of the virus as a result of 
continued viral replication.145 A significant genetic evolution 
in monocytes was also observed, and in some individuals on 
suppressive therapy monocyte strains were phylogenetically 
linked with circulating plasma variants.145 These findings 
suggest that monocytes may constitute a continuing source 
of infectious virus during HAART regardless of the length 
of treatment.
The circulating monocyte population is heterogeneous 
consisting of several subsets. The majority express high levels 
of CD14 and little or no CD16, described as CD14hi.147 The 
normal pathways of monocyte migration and trafficking 
may also define a mechanism by which HIV is distributed 
to various compartments around the body. After leaving the 
bone marrow, monocytes remain in circulation for between 
two and four days before migrating through the endothelial 
walls of capillaries and undergoing differentiation into tissue 
macrophages. Alternatively they may differentiate into DCs 
and enter the lymphatic system. HIV-infected monocytes 
can thus migrate to a variety of different sites around the 
body, and are likely to be responsible for colonization and 
continued turnover in diverse tissue compartments such as 
the CNS.148 The early establishment of HIV infection in HIV/AIDS - Research and Palliative Care 2010:2 111
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monocytes and the ongoing replication and persistence of 
HIV in this compartment represents a considerable challenge 
for antiretroviral drug regimens.
Dendritic cells
Dendritic cells (DCs) are professional antigen-presenting 
cells that play a major role in HIV pathogenesis. Langerhans 
cells, a DC subset residing in epithelial surfaces such as the 
skin, act as one of the primary, initial targets for HIV infec-
tion. Myeloid DCs (MDCs) and plasmacytoid DCs (PDCs), 
also professional antigen-presenting cells, are additional 
targets of HIV . As part of the normal immune response, DCs 
capture virions at the site of transmission in the mucosa, and 
migrate to the lymphoid tissue where they are responsible 
for large-scale infection of CD4+ T lymphocytes. Thus, 
dendritic–T cell interactions in lymphoid tissue, which are 
critical in the generation of immune responses, are also a 
major catalyst for HIV replication and expansion. Exposure 
of HIV to DCs may also impair the antigen-presenting 
capacity of these cells resulting in inadequate expansion of 
HIV-specific T cell responses.
Langerhans cell progenitors are derived from the bone 
marrow,149 and home to epithelial surfaces where they remain 
in a resting or immature state until they encounter antigens. 
Immature Langerhans cells possess a highly active endocytic 
system for efficient antigen processing.150 Langerhans cells 
were the first DCs to be reported as target cells for HIV 
infection.151
Viral attachment to DCs occurs via cell surface 
interactions that are dissimilar to those of regular HIV 
infection. Viral attachment to the surface of DCs is medi-
ated by C-type lectins including: DC-SIGN (dendritic 
cell-specific intercellular adhesion molecule-3-grabbing 
nonintegrin);152 langerin; and the mannose receptor.153 Viral 
attachment via these receptors can be followed by internal-
ization and/or subsequent transfer to permissive T cells.154 
Internalized HIV can be stored in early endosomal com-
partments without degradation, while surface-associated 
HIV can remain infectious for several days and can be 
transmitted to CD4+ T cells.152,154 The migratory nature of 
DCs and their ability to recruit numerous T cells to lymphoid 
tissue identifies them as strong candidates for a central role 
in spreading HIV within the host.155 A large number of 
DCs accumulate rapidly in the lymphoid tissue in the first 
weeks after infection,156 coinciding with a massive increase 
in the numbers of productively infected CD4+ T cells in the 
lymphoid tissue.157 In addition, HIV replicates in clusters 
of DCs and CD4+ T cells in lymphoid tissue throughout the 
course of the disease.158 Reflecting this, the FDC network 
in lymphoid tissues is a major site of HIV storage in both 
presymptomatic and the late stages of disease, and FDCs 
are recognized as the major source of viral RNA in this 
compartment.16
B cells
During infection with HIV, a large number of virions are 
detectable in the follicular areas of lymphoid tissues. Most 
of this virus is trapped on the surfaces of FDCs as immune 
complexes along the network of dendrites, which play a 
critical role in antigen mediated interactions with both 
T cells and B cells.159 FDC networks in the germinal centers 
account for the bulk of HIV RNA.96 It has recently been 
demonstrated that B cells in both lymphoid tissue and the 
peripheral blood carry replication competent virus attached 
on their surfaces.160 The mechanism of B cell binding to 
the virus is similar to that of DC, involving the binding of 
HIV-containing immune complexes to CD21 on the B cell 
surface.160,161 Virus bound to B cells can efficiently infect 
activated CD4+ T cells through cell-to-cell contact,160 and 
HIV in the form of immune complexes bound to B cells 
is more stable and more efficiently passed on to CD4+ 
T cells than free viral particles. These studies led to the 
suggestion that B cells may represent an important link 
between trapped virus on FDCs and virus replicating in 
CD4+ T cells.
A more recent study examined the genetic relationships 
between HIV bound to B cells and viruses in both 
CD4+ T cells and plasma.162 HIV bound to peripheral 
blood B cells was found to be closely related to virus in 
CD4+ T cells, and more divergent from virus in plasma.162 
HIV bound to lymph node-derived B cells and CD4+ 
T cells were similar, and showed an equivalent divergence 
from HIV bound to peripheral blood B cells. In addition, 
both were more distantly related to circulating CD4+ T 
cells.162 These findings gave evidence of a close association 
between virus circulating on B cells and virus replicating 
on CD4+ T cells, and a significant degree of trafficking 
between viruses from B cells and CD4+ T cells of the lymph 
nodes. Thus it is likely that in addition to FDCs, B cells 
may also contribute to ongoing replication by serving as 
an extracellular reservoir of HIV.
Natural killer cells
Natural killer (NK) cells are defined phenotypically as 
a CD3 negative lymphocyte subset that functions as a 
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markers including CD56, CD16, CD57, NKR-P1, how-
ever these markers may also be expressed on T lympho-
cytes.163 The majority of NK cells can be discriminated 
on the basis of CD56 expression, with the majority being 
CD56dimCD16+, which have a higher cytotoxic potential. 
The smaller CD56brightCD16dim/neg NK cell subset has 
higher cytokine producing potential. Resting CD56bright 
and CD56dim subsets also show differences in their 
expression of NK receptor repertoires.164 NK cells are 
pivotal in innate immunity against viruses and tumors. They 
can spontaneously kill virally infected cells without prior 
antigen stimulation and thus participate in early immune 
defense mechanisms prior to the establishment of adaptive 
responses. NK cells have direct cytotoxic and also perform 
non-cytolytic functions such as the secretion of cytokines 
which later modulate adaptive responses.164
Recently a subset of CD56+ CD16+ CD3- NK cells was 
identified which express both CD4 and the chemokine 
coreceptors CCR5 and CXCR4.165 This previously unchar-
acterized NK cell subset was shown to be productively 
infected in vitro by both X4 and R5 strains via a CD4-
mediated mechanism. Further characterization of NK cells 
purified from HIV-infected individuals receiving HAART 
demonstrated the presence of viral DNA, and virus could 
be recovered from these cells in culture.165 Longitudinal 
analysis revealed persistent infection of this NK cell sub-
set suggested a substantial contribution of viral DNA to 
the total pool in peripheral blood mononuclear cells, and 
showed that current antiretroviral therapies fail to eliminate 
the virus from this compartment.165 These findings raise the 
possibility that early defects in innate immune responses of 
HIV-infected individuals,166 may derive at least in part from 
the HIV infection of NK cells.
Tissue compartmentalization  
of HIV
The central nervous system
The CNS is one of the best examples of HIV compartmen-
talization. The CNS is a key anatomical reservoir of HIV in 
both therapy-experienced and therapy-naïve patients, and 
independently evolving HIV variants have been detected in 
diverse areas of the CNS, and which are genetically distinct 
from those circulating in the blood.167–169 HIV gene sequences 
in the V3 loop may confer neurotropism as well as neuro-
virulence.65 Brain-derived isolates are macrophage tropic 
and their env sequences tend to exhibit negative or neutral 
charges compared to those in the blood.
As discussed previously, the CNS is protected by the 
blood–brain barrier which tightly segregates the brain from 
the circulating blood, and the blood–cerebrospinal fluid 
barrier in the epithelium of the choroid plexus, which limits 
the passage of molecules and cells into the cerebrospinal 
fluid. This barrier-mediated separation of the CNS gives rise 
to an altered immunological environment, and also provides 
an obstacle to therapeutic measures such as antiretroviral 
therapy. Much of the HIV compartmentalization arising in 
the CNS relates directly to antiretroviral drug resistance. 
This primarily stems from inadequate drug penetration 
into the CNS, a major shortcoming of current HAART 
regimens. Inadequate drug penetration into the CNS is of 
concern firstly as the CNS may form a drug sanctuary for 
HIV, and secondly because the suboptimal concentration 
of drugs in this compartment favors the emergence of drug 
resistance.
HIV protease inhibitors have limited penetration into 
the brain. This poor transport through the blood–brain 
barrier is mainly due to active efflux by proteins; such as 
P-glycoprotein (P-gp), which prevent drugs from clearing 
virus from the CNS.170,171 Most protease inhibitors (PIs), 
including ritonavir and saquinavir, are P-gp substrates.170,171 
P-gp is an active drug-transporter of the ATP binding cassette 
transporter family and possesses a wide substrate range.172 
As P-gp transports its substrates in an outward (extracellular) 
direction, it blocks PIs from moving across the blood–brain 
barrier.170,173 Humans have only one drug-transporting P-gp, 
MDR1, which seems to carry out the same functions as the 
mouse Mdr1a and Mdr1b P-gps.170 The poor penetration 
of different antiretroviral drugs extends to different 
regions within the brain, which also show variability in the 
distribution of antiretroviral drug resistance.174 Regional 
variability in the incidence and frequency of HIV encephalitis 
lesions have also been described,175 and localization of 
viral RNA and DNA in the brain has also been reported.175 
However the mechanisms for this viral localization within 
the brain are still unclear.
Semen and the reproductive tract
Semen is a complex mixture of fluids from several organs 
including the testis, epididymis, seminal vesicles, prostrate 
and seminal ducts.176 The fluid component of semen is derived 
from the accessory glands, and the levels of seminal HIV RNA 
usually correlate with blood plasma RNA levels, although it 
has been shown to increase with genital tract inflammation 
from sexually transmitted diseases.177 HIV-infected cells in 
semen include lymphocytes and macrophages.70 The male HIV/AIDS - Research and Palliative Care 2010:2 113
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genital tract contains unique vascular features such as the 
blood–testis barrier. The function of the blood–testis barrier 
is to protect germ cells from harmful influences; however, it 
also impedes the delivery of chemotherapeutic drugs to the 
testis. The barrier has three components: firstly it contains a 
physicochemical barrier consisting of continuous capillaries; 
Sertoli cells in the tubular wall, connected together with 
narrow tight junctions; and a myeloid-cell layer around the 
seminiferous tubule. Secondly, it has an efflux-pump barrier 
containing P-gp and multidrug-resistance-associated protein1 
(MDR1); and thirdly, it has an immunological barrier consist-
ing of Fas ligand on Sertoli cells.178
These features provide a distinct environment for HIV 
replication, and hinder access of PIs into the germ cell 
compartment. Compartmentalization of HIV in the male 
genital tract has been described by numerous studies based 
on phylogenetic comparisons between blood and semen,179 
and the rate and pattern of the emergence of drug resistance 
in blood and semen.180 Distinct resistance patterns are likely 
to arise from the compartmentalization of viral replication 
and suboptimal concentrations of drugs in semen.
Studies have found genotypic differences between HIV 
in blood and HIV in female genital tract secretions.181 The 
mechanisms of this compartmentalization are uncertain, 
particularly as there is no anatomical barrier to entry in 
this compartment as in the male genital tract. It is probable 
that the genetic differences in this location arise from a 
founder effect, whereby virions migrate to a new tissue and 
proliferate, followed by localized evolution.182 However, 
selection may also shape the distinct viral populations,183 
and immune pressures are also likely to contribute. Local 
conditions including sexually transmitted infections 
and co-receptor expression on host cells may also be a 
factor.
Gastrointestinal mucosa
In addition to the distinctive cellular characteristics of 
lymphocyte populations in gastrointestinal mucosa, genetic 
and molecular differences in HIV-1 quasispecies isolated 
from this compartment have also been demonstrated. Viral 
isolates from gastrointestinal mucosa have been shown to 
have a greater propensity to induce cytopathology than blood 
derived isolates,184 and may differ phenotypically with respect 
to syncytium induction.185 Genotypic differences in the env, 
pro and RT genes have also been reported,186 supporting the 
presence of anatomically distinct, independently evolving 
viral quasispecies in this compartment. Despite this, a recent 
study reported that there were no significant differences in 
viral tropism or co-receptor utilization between isolates from 
mucosal and peripheral blood mononuclear cell (PBMC) 
compartments. The pattern of antiretroviral drug resistance in 
gastrointestinal mucosa has been demonstrated to be similar 
to that of the PBMC compartment, and in most cases those 
of plasma viral populations.187
Kidney epithelium and lungs
Recent molecular characterization of HIV quasispecies 
in the renal compartment has revealed evidence of tissue-
specific evolution. Phylogenetic trees constructed from 
HIV V3-loop or gp120 sequences of HIV DNA derived 
from renal epithelial cells and PBMC showed that kidney-
derived sequences clustered separately within the radiation 
of blood mononuclear cell-derived viral sequences.88 This is 
best explained by a stochastic event representing a founder 
effect following the initial seeding of kidney epithelium by 
a blood-derived variant.88
Discordant mutation patterns in the reverse transcriptase 
and protease genes have been observed in HIV isolates 
derived from plasma and cell free bronchoalveolar lavage 
fluid.86 Likewise, HIV DNA recovered from PBMC and cells 
from bronchoalveolar lavage fluid showed discordant patterns 
of drug resistance mutations in some cases.86
Cellular compartmentalization  
of HIV
Plasma and PBMC
The archiving of HIV in PBMC complicates the relationship 
between cell-associated and cell-free HIV circulating in 
the blood. There are multiple sources of circulating plasma 
virus in addition to PBMC, and the antiretroviral therapy 
is likely to suppress viral replication more efficiently in 
some compartments than others. Longitudinal analyses of 
plasma HIV RNA and proviral DNA have demonstrated 
significant differences between the frequencies of envelope 
sequence variants in the plasma and PBMC populations 
at any given point-in-time in asymptomatic patients.188 
Similarly, continual evolution and compartmentalization 
of HIV drug resistance between plasma and PBMC has 
been observed over time during HAART.189 Another study 
found that therapy was able to reduce plasma HIV RNA to 
below the level of detection, but PBMC associated RNA was 
not suppressed. In addition, CD4 counts correlated more 
with PBMC HIV RNA levels.190 More recently, a report 
comparing HIV derived from lymph nodes and blood con-
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sources other than CD4+ T cells in the peripheral blood 
and lymph nodes.162
Resting memory CD4+ T cells
The most notable example of HIV compartmentalization 
at the cellular level is the latent CD4+ T cell reservoir. 
Compartmentalization of HIV results from these cells 
remaining inactivated and persisting for long periods of 
time, which significantly impacts on the ability of HIV 
to turnover and evolve. Persistently infected, inactivated 
CD4+ T lymphocytes191 are also a major obstacle to viral 
eradication. Resting CD4+ T cells harboring provirus have 
been demonstrated in patients receiving HAART with 
undetectable plasma virus concentrations for extended time 
periods, and replication competent virus can be recovered 
from these cells after CD8+ T cell depletion in vitro.192 
The reservoir is established soon after primary HIV 
seroconversion, and can be activated by proinflammatory 
cytokines and bacterial products in vitro and poten-
tially in vivo. The latent replication-competent virus is 
predominantly found in resting memory (CD4+ CD45RO+) 
cells and at significantly lower levels in resting naïve (CD4+ 
CD45RA+) cells. Evidence has shown that virus in the latent 
CD4+ T cell reservoir is mainly CCR5 tropic,193 and contains 
fewer drug resistance mutations than circulating plasma 
strains.24 These findings are therefore in agreement with the 
reservoir being established soon after infection. The pres-
ence of unintegrated HIV-1 DNA in infected resting CD4+ 
T cells from patients with undetectable plasma viremia also 
suggests persistent and active viral replication in vivo.191 This 
is most likely to be responsible for the continued low-level 
viral turnover and evolution observed in patients thought to 
be fully suppressed by HAART.194
Macrophages
Macrophages produce and release high levels of virus over 
an extended time period,132 categorizing them as chronically 
and persistently infected cells.6 They are insensitive to the 
cytopathic effect of the virus and have an extended long life 
span. It is unclear whether HIV populations in macrophages 
are truly compartmentalized, but several features of their 
infection warrant interest. First and most notably, latent 
infection is widespread in macrophages throughout the 
lymphoid system, from early to late stages of infection.139 
Secondly, it has been shown that there are differences in 
the infectivity of viruses produced by macrophages,125 
indicating that HIV may evolve differently in these cells. 
Finally, the unusual dynamics of replication in macrophages 
and the unique characteristics of these cells result in altered 
responses to antiretroviral therapy. Although nucleoside 
reverse transcriptase inhibitors (NRTIs) are potent inhibitors 
of HIV replication in macrophages,195 PIs show reduced 
activity requiring much higher dosages for a desirable effect; 
a feature that could be attributable to P-gp-mediated drug 
clearance.
Drug penetration, viral reservoirs 
and drug resistance
Poor penetration of antiretroviral  
drugs in the CNS
There is considerable evidence showing that unique 
anatomical structures, which limit the distribution of antiret-
roviral drugs into the CNS, the blood–brain barrier and the 
blood–CSF barrier primarily formed by the choroid plexus. 
High plasma protein-binding of protease inhibitors and 
their unidirectional efflux by P-gp membrane proteins in the 
blood–brain barrier limit CNS penetration and absorption of 
antiretrovirals.170,171 Thus, the CNS represents a site where 
ongoing viral replication may occur. Mutations confer-
ring resistance to multiple antiretroviral drug classes may 
also predominate in compartments where drug levels are 
suboptimal.
Suboptimal drug penetration also influences the 
emergence of multiply drug-resistant variants, which may 
also predominate in this anatomical reservoir. Discordant 
changes in the peripheral blood and CSF HIV-1 RNA levels 
have been reported in response to antiretroviral therapy. Simi-
lar and discordant patterns of antiretroviral drug resistance 
have been detected in the RT and protease genes of isolates 
from the blood compartment and the CSF of the same 
patient.196 Better understanding of how drug-resistant muta-
tions emerge in HIV populations in vivo, and the develop-
ment of more efficacious antiretroviral drugs is of paramount 
importance to achieve and maintain consummate therapeutic 
drug levels in blood or brain.
Drug penetration in blood leukocytes
A similar scenario of differential penetration and bioavailability 
of anti HIV drugs also applies to blood leukocytes. To help 
ensure that adequate drug concentrations are achieved 
throughout the dosing interval, therapeutic drug monitoring 
of the anti-HIV drugs (such as PIs) in plasma is commonly 
used. The drugs show differential accumulations within 
lymphoblastoid cell lines and peripheral blood mononuclear 
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nelfinavir  saquinavir  lopinavir  ritonavir  indinavir. 
Furthermore, drug concentrations in vivo can also vary 
considerably between cell/tissue types during HAART.197 
Differences in drug concentrations can be attributed to the 
variable penetration of antiretroviral drugs which, in turn, is 
influenced by multispecific drug transporters such as: organic 
anion transporting polypeptides (OATPs); the MDR1 (P-gp); 
as well as multidrug resistance-associated proteins (MRP). 
It is also known that cell lines expressing high levels of 
P-gp significantly reduce the accumulation of HIV-PI, and 
are less sensitive to HIV-PI antiviral activity than cell lines 
not expressing P-gp.198 These proteins work in concert with 
detoxification enzymes to protect the organism/living cells 
from potentially harmful compounds.16,199
Possible relationship between  
drug transporter concentrations  
and drug levels
Recently, Lucia and colleagues200 demonstrated differences in 
the levels of P-gp and MRP in T lymphocytes of HIV patients. 
They have also shown that protease inhibitors contribute to 
P-gp efflux function in major cell targets for HIV-1 such as 
CD4+ and CD34+ progenitor cells. These data suggest that 
drug level studies in different cell types of HIV patients are 
vital to gain a clear understanding of the expression of drug 
transporter proteins and their relationship with the emergence 
of cellular drug resistance and drug levels.
New approaches to eradicate  
viral reservoirs
It is now apparent that HAART does not provide a complete 
elimination of HIV from the infected host. If the treatment 
is stopped, residual virus concealed in several potential 
reservoir sites can rapidly expand, thereby allowing disease 
progression to occur. Therefore, investigations concerning 
the sources of persistent replication-competent HIV during 
HAART and strategies to purge these reservoirs remain the 
top priority in HIV treatment. Memory cells are long-lived 
host cells and HIV can successfully tamper with this unique 
feature of memory cells and can then persist for decades 
with its inert and metabolically inactive viral cargo. Upon 
receiving a stimulatory signal the cell activates, which 
concomitantly induces the production of viral progeny from 
the latent HIV genome. T cells also decay very slowly during 
HAART, with an average half-life of 44 months, and thus 
it is estimated that with the currently prescribed regimen to 
HIV patients, complete eradication of this reservoir would 
take over 60 years. Thus, viral reservoir establishment in 
HIV patients is a serious obstacle to the long-term success 
of antiretroviral treatment, especially in those reservoirs that 
restrict the penetration of various antiretroviral drugs.
There has been considerable interest in developing 
potential approaches for diminishing, containing and 
eliminating latent reservoirs of HIV in the infected hosts; 
however, to date, all these approaches have received skeptical 
reception at best because of the nature and complexity of 
viral reservoirs in the human host. Although no successful 
approach has emerged as a winner in effectively targeting viral 
reservoir sites, several options for treatments that are targeted 
at eliminating HIV-infected cells capable of producing 
replication-competent virus in specific anatomical and cellular 
reservoirs are presently being explored. As a vaccine is still 
some distance away from being used as a preventative mea-
sure against HIV infection, additional therapies to HAART 
that target viral reservoirs are clearly needed. These are the 
treatments that will be aimed at eliminating viral reservoirs 
or at least preventing their long-term establishment, which 
can provide a glimmer of hope for the future. Some of these 
key strategies are discussed below.
Activating persistently and latently 
infected resting CD4+ T cells
Given the complexity of pre-integration and post-integration 
latency in HIV reservoirs, it is difficult to devise a strategy 
that can provide sustainable eradication of HIV from the 
reservoir sites, where most of the latent virus is concealed. 
Most strategies targeting reservoirs involve activating the 
latently infected cells in order to induce expression from the 
HIV genome. As a consequence, the cell will become infected 
and killed either via cytopathic effects induced by HIV or 
by host immune effector mechanisms. This, in turn, can be a 
viable platform to halt virus spread through HAART during 
the stimulation phase. Though a few stimulants are known, 
interleukin-7 (IL-7), in particular is able to rekindle latent 
virus from the reservoir site. IL-7 causes a substantial increase 
in the expression of latent HIV-1 from both human thymo-
cytes and peripheral T cells with minimal effects on T cell 
phenotype. Thus IL-7 remains a viable candidate in the fight 
for clearance of viral reservoirs. New therapies should target 
pathways downstream of homeostatic proliferation, including 
inhibitors of the IL-7 pathway or pathways associated with 
self-renewal and ‘stem cell-ness’, such as those being 
developed for treating of leukemias and cancers. Indeed, by 
limiting immune activation and affecting long-lived infected 
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the self-renewal of memory T cells, in association with 
HAART, will pave the way for the eradication of virus in 
aviremic individuals.106
Other molecules, which are capable of activating latent 
provirus include agents such as the non-tumor-inducing phor-
bol ester prostratin. Prostratin inhibits HIV infection and viral 
spread at the entry/fusion step of viral life cycle. The lack of 
tumor promotion of prostratin coupled with its ability to up-
regulate latent HIV-1 provirus expression and inhibition of 
viral infection are important features that could be exploited 
as an effective therapy to eliminate latent reservoirs.201 Histone 
deacetylase inhibitors such as valproic acid202 and certain modu-
lators of cellular microRNAs,202 can activate latent provirus. 
Unfortunately, to date, none of the strategies have translated 
clinically in effectively purging the latent virus from the reser-
voir sites. The caveat with these technologies is that robust viral 
activation can also lead to undesirable immune activation. Thus, 
further refinement is needed to their clinical translation.
Shock to kill approach using  
histone deacetylases
Savarino and colleagues have studied the so-called ‘barrier 
of latency’, which has been the main obstacle to eradicating 
HIV from the body.203 Cells harboring a quiescent virus are 
responsible for HIV persistence during therapy. They have 
found a new way that could drive out the stubborn virus 
from infected cells so that the body’s immune system or 
drugs have a chance to kill them.203 A class of inhibitors 
called histone deacetylases, which keep HIV in its dormant 
state, only work at toxic doses. Histone deacetylase (HDAC) 
is a host mediator of gene repression, which inhibits HIV 
gene expression and virus production thereby contributing 
to quiescence of HIV within resting CD4 T cells.204 A 
recent proof of concept study by Lehrman and colleagues202 
showed that combination therapy with an HDAC inhibitor 
and intensified HAART safely accelerates the clearance of 
HIV from resting CD4+ T cells in vivo, suggesting a new 
and practical approach to eliminate HIV infection in this 
persistent reservoir. However, extensive patient-based studies 
are required to support this proof of concept study. Moreover, 
the beneficial effects of this drug are visible on HIV only 
when used in toxic concentrations.
Furthermore, they have also shown203 that adding a 
second drug called buthionine sulfoximine along with HDAC 
‘awakens’ the infected cells at lower doses, while leaving the 
virus-free cells intact. It appears that at non-toxic quantities, 
class I HDAC inhibitors were able to induce the ‘awakening’ 
of a portion of cells within a latently infected cell population. 
The researchers then repeated the experiment adding a drug 
inducing oxidative stress, buthionine sulfoximine (BSO). 
The results showed that BSO was able to recruit cells 
non-responsive to the HDAC inhibitors into a responding 
cell population. Clearly evident was that the infected 
cells’ ‘awakening’ was followed by cell death, whereas the 
non-infected cells were spared by the drug combination.
Enhanced killing approach
Methods for enhanced killing of recently activated HIV-
infected cells are also being investigated. One such example 
is immunotoxins, which are composed of a targeting domain 
derived from a monoclonal antibody linked to a toxic moiety. 
For this purpose, the immunotoxin specifically targeting 
cells expressing the HIV envelope protein have been used 
to deplete both latently infected T cells205 and infected 
macrophages206 after upregulation of HIV gene expression 
with stimulants. ‘Activation-elimination’ strategies such 
as this may therefore accelerate clearance of HIV from its 
various cellular reservoirs. Moreover, if this type of approach 
were used in conjunction with post-exposure vaccination 
or genetically modified stem cell immune reconstitution 
strategies, it might prove even more effective in decreasing or 
eliminating latent and persistent viral reservoirs. While many 
of the approaches outlined above are still at the developmental 
stages and are not without limitations, it is hoped that some 
of these nascent strategies will rapidly advance to the point 
that they can provide benefits to patients.
Gene-based induction therapy 
targeting latent reservoirs  
of HIV-1
One approach to eradication of the latent reservoir is 
induction therapy, whereby latently infected cells are 
activated to initiate viral replication. Herpes virus saimiri 
protein StpC has been shown to enhance HIV-1 replication 
in MOLT4 cells, suggesting it may be a useful tool for 
induction therapy.207 An induction vector containing StpC 
and a suicide gene such as Herpes simplex virus thymidine 
kinase (TK) may be utilized as a novel treatment targeting 
latently infected cells. Turner and colleagues207 have shown 
that the transfection with a suicide vector based on StpC 
and TK increased HIV-1 replication compared to cells 
transfected with a vector containing TK alone. The addition 
of ganciclovir resulted in reduced HIV-1 p24 levels in the 
cells transfected with the StpC-TK vector. This study provides 
proof of concept that gene induction therapy using suicide 
vectors encoding StpC to target cells latently infected with HIV/AIDS - Research and Palliative Care 2010:2 117
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HIV-1 may offer a new approach to treating latent HIV-1. 
These studies will lead to a better understanding of viral 
latency and its disruption; and will assist development of 
improved techniques towards targeting latent reservoirs.
Genetic therapies against HIV
In the absence or presence of chemotherapy, gene therapy offers 
some hope of combating HIV infection via sustained interfer-
ence with HIV replication in vivo. It is believed that the emer-
gence of viral resistance and the establishment of reservoirs 
seen during HAART are the biggest impediments to successful 
HAART. These may possibly be addressed by gene therapies 
that use combinations of genetic agents for inhibiting both viral 
and host gene targets. Several of these strategies have already 
been or are being tested in planned clinical trials. These include, 
RNA-based agents (ribozymes, antisense, RNA aptamers and 
small interfering RNA (RNAi), protein-based agents, (mutant 
HIV Rev protein M10, fusion inhibitors, zinc-finger nucleases, 
dominant-negative proteins, intrabodies, intrakines). Recent 
advances in T-cell–based strategies include: gene-modified 
HIV-resistant T cells; lentiviral gene delivery; CD8+ T cells; 
T bodies; and engineered T-cell receptors. HIV-resistant hema-
topoietic stem cells have the potential to protect all cell types 
susceptible to HIV infection.
Overall, of several gene therapies tested so far none have 
fared successfully. Viral escape is a major problem, which 
will and has confounded every gene therapy approach tried to 
date. Although cellular targets are far less prone to mutational 
escape, the long-term side effects are unclear. Another major 
confounding factor is the specific targeting of the anti-HIV 
gene to have maximal effect against HIV-1 coupled with 
minimal cellular toxicity.
Conclusions
Even though eradication of HIV in the infected host appears 
to be extremely complex and challenging with the currently 
prescribed antiretroviral drugs, researchers should not 
abandon the goal of finding ways to challenge HIV , and devel-
oping strategies for either the long-term containment of HIV 
replication and prevention of immune dysfunction during 
HIV infection, or flushing out HIV from the reservoir sites 
in vivo. Although the latter has proven extremely difficult, it 
will need a coordinated effort and innovative thinking from 
scientists and clinicians alike.
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